Aegerion Pharmaceuticals, Inc. - FORM S-1/A - EX-23.3 - CONSENT OF L.E.K. CONSULTING, LLC - October 7, 2010

Attached files

file filename
S-1/A - S-1/A #2 - Aegerion Pharmaceuticals, Inc.ds1a.htm
EX-5.1 - OPINION OF GOODWIN PROCTER LLP - Aegerion Pharmaceuticals, Inc.dex51.htm
EX-3.2 - FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - Aegerion Pharmaceuticals, Inc.dex32.htm
EX-4.1 - SPECIMEN CERTIFICATE EVIDENCING SHARES OF COMMON STOCK - Aegerion Pharmaceuticals, Inc.dex41.htm
EX-1.1 - FORM OF UNDERWRITING AGREEMENT - Aegerion Pharmaceuticals, Inc.dex11.htm
EX-3.3 - BY-LAWS - Aegerion Pharmaceuticals, Inc.dex33.htm
EX-3.4 - FORM OF AMENDED AND RESTATED BY-LAWS - Aegerion Pharmaceuticals, Inc.dex34.htm
EX-3.1 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - Aegerion Pharmaceuticals, Inc.dex31.htm
EX-10.5 - EMPLOYMENT AGREEMENT WITH JOHN CAVAN - Aegerion Pharmaceuticals, Inc.dex105.htm
EX-10.1 - 2006 STOCK OPTION AND GRANT PLAN, AS AMENDED - Aegerion Pharmaceuticals, Inc.dex101.htm
EX-23.1 - CONSENT OF ERNST & YOUNG LLP - Aegerion Pharmaceuticals, Inc.dex231.htm
EX-21.1 - SUBSIDIARIES OF AEGERION PHARMACEUTICALS, INC. - Aegerion Pharmaceuticals, Inc.dex211.htm
EX-10.9 - LOAN & SECURITY AGREEMENT, AS AMENDED - Aegerion Pharmaceuticals, Inc.dex109.htm
EX-10.2 - 2010 STOCK OPTION AND INCENTIVE PLAN - Aegerion Pharmaceuticals, Inc.dex102.htm
EX-10.7 - LICENSE AGREEMENT WITH BAYER HEALTHCARE AG - Aegerion Pharmaceuticals, Inc.dex107.htm
EX-10.15 - FORM OF NOTE ISSUED UNDER THE FOURTH AMENDED & RESTATED NOTE - Aegerion Pharmaceuticals, Inc.dex1015.htm
EX-10.18 - EMPLOYMENT AGREEMENT WITH WILLIAM H. LEWIS - Aegerion Pharmaceuticals, Inc.dex1018.htm
EX-10.14 - FOURTH AMENDED & RESTATED NOTE PURCHASE AGREEMENT - Aegerion Pharmaceuticals, Inc.dex1014.htm
EX-10.4 - EMPLOYMENT AGREEMENT WITH CHRISTINE PELLIZZARI - Aegerion Pharmaceuticals, Inc.dex104.htm

Exhibit 23.3

Consent of L.E.K. Consulting LLC

L.E.K. Consulting LLC (“L.E.K.”) hereby consents to the use of L.E.K.’s name, and the statements attributed to L.E.K., in the Amendment No. 2 to the Registration Statement of Aegerion Pharmaceuticals, Inc. on Form S-1 filed with the Securities and Exchange Commission on October 7, 2010 (the “Amendment No. 2”), and all amendments thereto, provided that any modifications to the use of L.E.K.’s name or the statements attributed to L.E.K. shall be subject to the prior consent of L.E.K.

 

L.E.K. Consulting LLC

By:

  

/s/ Shuba Satyaprasad

Name:

   Shuba Satyaprasad

Title:

   Internal Counsel

October 6, 2010

Boston, MA

Aegerion Pharmaceuticals, Inc. Reports